Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6.43 USD +6.28% Intraday chart for Candel Therapeutics, Inc. +17.77% +337.41%
Apr. 11 Sector Update: Health Care Stocks Decline Thursday Afternoon MT
Apr. 11 Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Decline Thursday Afternoon
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday
Top Premarket Gainers
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial
Top Midday Gainers
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
Candel Therapeutics Gets FDA Fast Track Label For Treatment of Recurrent High-Grade Glioma
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
Candel Therapeutics, Inc. Announces Executive Changes
Candel Therapeutics, Inc. Announces Executive Changes
Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CADL Stock
  4. News Candel Therapeutics, Inc.
  5. Other languages